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Abstract
Patients with Alzheimer’s disease (AD) exhibit substantial accumulation of amyloid-b (Ab) plaques in the brain. Here, we
examine whether Ab vaccination can facilitate the migration of T lymphocytes to specifically target Ab plaques and
consequently enhance their removal. Using a new mouse model of AD, we show that immunization with Ab, but not with
the encephalitogenic proteolipid protein (PLP), results in the accumulation of T cells at Ab plaques in the brain. Although
both Ab-reactive and PLP-reactive T cells have a similar phenotype of Th1 cells secreting primarily IFN-c, the
encephalitogenic T cells penetrated the spinal cord and caused experimental autoimmune encephalomyelitis (EAE),
whereas Ab T cells accumulated primarily at Ab plaques in the brain but not the spinal cord and induced almost complete
clearance of Ab. Furthermore, while a single vaccination with Ab resulted in upregulation of the phagocytic markers
triggering receptors expressed on myeloid cells-2 (TREM2) and signal regulatory protein-b1 (SIRPb1) in the brain, it caused
downregulation of the proinflammatory cytokines TNF-a and IL-6. We thus suggest that Ab deposits in the hippocampus
area prioritize the targeting of Ab-reactive but not PLP-reactive T cells upon vaccination. The stimulation of Ab-reactive T
cells at sites of Ab plaques resulted in IFN-c-induced chemotaxis of leukocytes and therapeutic clearance of Ab.
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Introduction
Alzheimer’s disease (AD), an age-related neurodegenerative
disorder, is the most common cause of dementia. The disease is
identifiable by the accumulation of amyloid beta (Ab) in the
hippocampal and cortical areas of the brain [1], often associated
with neurofibrillary tangles caused by hyperphosphorylation of the
cytoskeleton protein Tau [2]. Ab appears to exert a toxic effect on
neurons—both directly in its oligomeric form [3] and indirectly in
the form of dense plaques—by inducing chronic activation of
microglia and astrocytes [4].
The role of T cells in central nervous system (CNS) tissue has
been widely studied in recent years. Findings have primarily
implicated CNS-specific CD4 T cells in the pathology of
experimental autoimmune encephalomyelitis (EAE), where mye-
lin-specific T cells penetrate the CNS and promote axon
demyelination there [5,6,7,8,9]. Despite the pathogenic role of T
cells in mouse models of multiple sclerosis (MS), brain-specific T
cells evidently play beneficial roles in non-autoimmune neurode-
generative processes, such as those occurring in Alzheimer-like
disease [10,11], brain injury [12,13], amyotrophic lateral sclerosis
[14] and stroke [15]. Activities in which these specific T cells, or
the cytokines they produce, were found to participate include
increased uptake of cell debris by microglia [16], release of anti-
inflammatory cytokines [17], increased expression of neurotrophic
factors [11,18,19], increased capacity for buffering of glutamate
toxicity[20], and enhanced neurogenesis [21,22,23,24]. We
recently demonstrated the presence of Ab-specific T cells in the
repertoires of human subjects, depending primarily on their HLA–
DR genetic backgrounds [25,26]. We showed that the frequency
of these T cells is significantly increased both in elderly healthy
individuals and in patients with AD [25]. We also characterized
the specificities of such T cells in humanized mouse AD models
expressing frequent HLA–DR alleles [26].
Interferon (IFN)-c is a natural-killer (NK)-cell and T-cell-
derived protein that plays a key role in the effector function of the
immune system against invading pathogens, activating microglia
to fully potent antigen-presenting cells [27] and enhancing the
expression of chemokines and cell-adhesion molecules required for
migration of T-cells to the brain [28]. However, beyond its
primary role in inflammation, recent findings demonstrate that
IFN-c expression is increased in the ageing brain [29] and exerts
neuroprotective effects [22,30,31,32,33,34]. To gain an insight
into the mechanisms by which Ab-specific T cells function at sites
of Ab plaques, we generated a mouse model of AD in which the
brain expresses IFN-c in small amounts that do not cause
spontaneous infiltration of bone marrow-derived cells, abnormal
glial activation, or neurological deficits [35]. A single immuniza-
tion of such mice with Ab, but not with the encephalitogenic
proteolipid protein (PLP 139-151), resulted in trafficking to the
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and enhanced the clearance of Ab.
Materials and Methods
Mice
C57BL6 and SJL mice were purchased from Harlan Israel.
APP-Tg mice (line J20) on a C57BL6 background expressing APP
under the platelet-derived growth factor promoter [36] were
kindly donated by Dr. Mucke. APP/PS1-Tg mice [37] were kindly
supplied by Dr. Mathias Jucker. Transgenic SJL mice expressing
IFN-c under the myelin basic protein promoter [35] were kindly
donated by Dr. Owens. Homozygous IFN-c-Tg mice were crossed
with either APP-Tg or APP/PS1-Tg mice to generate APP/IFN-c
or APP/PS1/IFN-c B6SJLF1 Tg mice, respectively. All surgical
and experimental procedures were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of Ben-
Gurion University of the Negev (Approval number IL-610904).
Immunization
Mice (9–10 months old) were immunized by injection into the
flank with Ab1-42 (100 mg) or proteolipid protein (PLP)139-151
(400 mg; GenScript Corp., Piscataway, NJ, USA) emulsified in
complete Freund’s adjuvant (CFA) H37Ra (Difco, Detroit, MI,
USA). The Ab1-42 peptide used for immunization was initially
dissolved in a small volume of DMSO to enhance its solubility and
then diluted in phosphate buffer saline (PBS) to 2 mg/ml. The
peptide existed primarily in a trimer form as indicated by gradient
gel (4–20%) electrophoresis and western blot analysis using the
6E10 anti-Ab monoclonal antibodies (data not shown) and as such
was emulsified with CFA to a final concentration of 1 mg/ml.
Pertussis toxin (PTX) (List Biological Laboratories, Campbell, CA,
USA) was injected i.v. (200 ng/mouse) on day 0 and again 48 h
later. EAE severity was scored as follows: grade 1, paralyzed tail;
grade 2, ataxic; grade 2.5, one hind leg paralyzed; grade 3, both
hind legs paralyzed; grade 3.5, three legs paralyzed; grade 4,
complete paralysis; grade 5, moribund.
Cytokine ELISA
Popliteal lymph nodes or spleens of immunized APP/IFN-c Tg
mice were harvested, and their cells (10610
6 cells/ml) were
cultured in U-shaped 96-well-plate culture dishes in DMEM
medium containing 10% fetal calf serum, 10 mM HEPES, 1 mM
sodium pyruvate, 10 mM nonessential amino acids, 1% Pen/Strep
and 50 mM b mercaptoethanol. Interleukin (IL)-2 and IL-4 were
measured in the supernatant after 24 h, IFN-c and IL-10 after
48 h, and IL-17A after 72 h, in each case with a sandwich ELISA
according to the manufacturer’s instructions (Biolegend, San
Diego, CA, USA).
Quantitative real-time PCR
Mice were anesthetized by i.p. injection of ketamine-xylazine
and perfused with ice-cold PBS buffer. The brain was removed
from the skull, and the hippocampus-cortex was excised on ice.
Total RNA was extracted with Bio-Tri RNA (Bio-Lab, Jerusalem,
Israel) according to the manufacturer’s instructions. Total RNA
(5 mg) was reverse
-transcribed using a Bio-RT kit (Bio-Lab,
Jerusalem, Israel) according to the manufacturer’s instructions.
The primers for real time (RT)-PCR were designed using Primer
Express software (Applied Biosystems, Warrington, UK) and
synthesized by Sigma. Real-time quantification of genes was
performed by means of a SYBER Green RT-PCR assay (Applied
Biosystems) using 125 ng of total cDNA for 20 ml of the RT-PCR
reaction mixture. Samples were run in triplicate, and the
expression level of each gene was compared with that of b-actin.
Amplification, detection of specific gene products, and quantitative
analyses were performed using the ABI PRISMH 7500 Sequence
Detection System (Applied Biosystems).
Immunohistochemistry
Mice were killed with an overdose of isoflurane, and their brains
were rapidly removed and placed in molds containing an OCT
compound (Tissue-Tek, Torrance, CA, USA). The tissues were
frozen in isopentane, cooled by liquid nitrogen, and stored at
280uC. Sagittal sections (12 mm) were taken throughout the
hippocampus and fixed in ice-cold methanol for 2 min, then in 4%
formaldehyde for 4 min, and then washed with DDW and PBS/
Tween (0.05%). Prior to staining, primary antibody diluting buffer
(Biomeda Corp., Foster City, CA, USA) was used to block
nonspecific binding. An avidin-biotin blocking kit (Vector Labs,
Burlingame, CA, USA) was used when sections were stained with
biotinylated primary antibodies. Sections were examined under an
Olympus Fluoview FV1000 laser scanning confocal microscope.
Axonal demyelination. For detection of myelin loss, frozen
brain sections were stained with Luxol Fast Blue solution (1%
Luxol fast blue, Sigma-Aldrich; 10% acetic acid, 95% ethanol) at
60uC for 2 h. Slides were rinsed in 95% ethanol and then in
DDW. They were then incubated in a 0.05% lithium carbonate
solution (Fluka Analytical) in DDW for 10 s, and then for 30 s in
70% ethanol followed by DDW for 30 s. These differentiating
steps were repeated until grey and white matter were clearly
distinguishable. Slides were then counterstained with 0.25% cresyl
echt violet solution (Fluka Analytical; 0.25% cresyl echt violet,
10% acetic acid in DDW) for 10 min at room temperature, and
washed in DDW and then in 70% and 100% ethanol. Finally,
slides were cleared and mounted with VectaMount (Vector Labs).
Antibodies
PECAM-1 (1:50), CD4 (1:50), CD8a (1:50), CD19 (1:50), and
CD11c (1:25) were all purchased from Biolegend, San Diego, CA,
USA. CD11b (1:25) was obtained from Serotec, Raleigh, NC,
USA. Rabbit anti-human Ab antibodies (1:500) were generated at
our animal facility and examined for specificity by ELISA and
immunohistochemistry. TO-PRO 3 (Invitrogen, Carlsbad, CA,
USA) was used in a 1:3000 dilution, and all subsequent secondary
antibodies or avidin were conjugated to Alexa-488, Alexa-546, or
Alexa-647 (Molecular Probes) diluted 1:500 and 1:800 for
antibodies and avidin, respectively.
Confocal imaging analysis
CD4/CD8 co-localization in the hippocampus. Brain
sections from immunized APP/IFN-c Tg mice were
immunostained with anti-CD4 and anti-CD8 for the analysis of
CD4 and CD8 T cells, respectively, and with PECAM-1 and Ab
to locate lymphocytes in the vasculature and Ab plaques,
respectively. Areas of the hippocampus, including the dentate
gyrus, were imaged with both the 106and 606objective lenses,
and T-cell subpopulations were counted manually.
Quantification of Ab plaques. APP/IFN-c Tg mice were
immunized with Ab, with or without injection of PTX. Brains
from untreated and treated mice were quantitatively analyzed for
Ab plaques using three–six sections (40 mm thick) per hemisphere
for accurate representation of the hippocampus area. Sections
were stained for Aband examined with a confocal microscope.
Fluorescence intensity was first obtained in sections from untreated
mice, and identical laser-scanning parameters were then used for
the entire experiment. Using Volocity 3D image analysis software
(Improvision, Waltham, MA, USA), we set an intensity threshold
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Fig. S1). The sum of the stained areas was calculated in three
regions of the hippocampus: 0.5–0.9 mm, 0.9–1.35 mm, and
1.35–1.8 mm mediolateral from the bregma (Mouse Brain Atlas,
Franklin and Paxinos 2007). The average of the summed
fluorescence area was calculated for each group per
hippocampus location (2–4 slices/location).
Results
Immunization of APP/IFN-c Tg mice with Ab, but not
with PLP, results in the accumulation of T cells primarily
at sites of Ab plaques
A previous study by our group demonstrated that small amounts
of IFN-c in the brain allowed lymphocyte migration to the brains
of APP-Tg mice upon eliciting Ab-specific Th1 type of immune
response [16]. Ab immunization of APP-Tg mice lacking IFN-c in
the brain, although elicited the same peripheral immune response,
did not result in T-cell occurrence at both the meningeal and
parenchymal tissues of the brain [16]. However, although APP is
expressed throughout the CNS, we observed certain differences in
Ab-immunized APP/IFN-c Tg mice with regard to the pattern of
T cells in the CNS compared to the pattern usually observed in
mice that develop EAE upon immunization with myelin peptides.
First, the target site of migration in the CNS was found to be the
brain but not the spinal cord [16]. Second, lymphocytes appeared
not to generate chronic lesions around the vessels but rather to
migrate further into the parenchyma. To test our hypothesis that
immunization of APP/IFN-c Tg mice with Ab, but not with an
encephalitogenic peptide, results in lymphocyte migration primar-
ily to sites of Ab plaques in the brain, we immunized mice with
Abor the encephalitogenic PLP peptide 139–151, and 19 days
later we co-stained brain sections for Ab, microglia and T cells.
We found that CD4 T cells (Fig. 1Aa and Supplemental data, Fig.
S2a-b) were co-localized with Ab plaques (Fig. 1Ab and
Supplemental data, Fig. S2c-d) and CD11b
+ microglia (Fig. 1Ac
and Supplemental data, Fig. S2e-f) primarily in areas of the
hippocampus, including the dentate gyrus, where accumulation of
Ab in this mouse model of the disease is more intense in the initial
deposition process [36]. A three-dimensional reconstructed image
demonstrated that lymphocytes at the core of the Ab plaque
deposition were co-localized with CD11b microglia (Fig. 1B). Co-
localization image analysis of CD4 T cells and Ab plaques
demonstrated that T cells in the brain were specifically targeted to
sites of Ab plaques (Fig. 1C).
In contrast to immunization with Ab, immunization of APP/
IFN-c Tg mice with PLP induced EAE with a clinical score of 2–3
(see EAE scoring scheme in Materials and Methods). In addition,
PLP immunization resulted in the appearance of CD4 T-cell
infiltrates in the spinal cord (Supplemental data, Fig. S3) and
cerebellum (Fig. 2Aa) and typical demyelinating lesions, as
indicated by Luxol Fast Blue staining (Fig. 2Ab, see arrows).
Moreover, although CD4+ (Fig. 2Ba and Supplemental data, Fig.
S4a-b) and CD11b+ (Fig. 2Bb and Supplemental data, Fig. S4e-f)
cells accumulated at the meninges following to PLP immunization,
only a few T cells were found in the hippocampus co-localized
with Ab deposits (Fig. 2B–C and Supplemental data, Fig. S4c-d).
To determine whether this difference in the migration pattern of
Ab- reactive and PLP- reactive T cells to the CNS of APP-Tg mice
resulted from the cytokine profile of the cells, mice were
immunized with Abor PLP and T cells were examined ex vivo
for cytokine secretion by ELISA. Notably, a similar Th1-cell
response was induced both after PLP and after Ab immunization
(Fig. 3). Upon antigen stimulation, T cells secreted primarily IL-2
as the growth factor cytokine and IFN-c and—though to a
substantially smaller extent—IL-17A as the effector cytokines
(Fig. 3A-B). No significant cytokine production was observed in
untreated or CFA-immunized mice upon Abstimulation (Fig. 3A).
Ab immunization of APP/IFN-c Tg mice results in
migration primarily of CD4 and CD8 T cells to the brain
parenchyma
To further characterize the location and type(s) of cells
infiltrating into the hippocampal and meningeal tissues of the
brain, APP/IFN-c Tg mice were killed 19 days after immuniza-
tion, and their brains were excised and processed for immunohis-
tochemistry. Both CD4 T cells (Fig. 4A) and CD8 T cells (Fig. 4B)
were observed in the meningeal (yellow arrowheads) and
parenchymal blood vasculature (red arrows). CD19 B cells were
found in the meninges (yellow arrowheads) and parenchymal
vessels (red arrows), but not in the parenchymal tissue (Fig. 4C).
No natural killer cells were observed anywhere in the brain at 14
to 19 days post-immunization (data not shown). In addition, co-
staining of Ab (blue), CD4 (red), and CD8 (green) T cells revealed
the occurrence of both of these lymphocyte subpopulations in the
perivascular space (Fig. 4D–E) and at amyloid plaques (Fig. 4E–F).
Quantification of CD4 and CD8 T cells in the brains of the Ab-
immunized mice revealed that CD4 effector T cells comprised the
dominant population (64.3%, whereas CD8 cells comprised
35.7%; n=3, SD=7.74). These data suggest that in Ab-
immunized mice these two T-cell subtypes not only cross the
blood–brain barrier but also home to amyloid plaques, where they
appear to be activated, presumably as a result of restimulation by
local antigen-presenting cells (APCs).
Ab immunization of APP/IFN-c Tg mice results in
effective clearance of Ab plaques co-localized with T cells
Post-mortem examination of AD patients vaccinated with Ab
has revealed clear evidence of plaque removal up to five years after
immunization [38,39]. To determine whether the activated T cells
residing at sites of Ab plaques could enhance the clearance of Ab
from the brain, we immunized 9-month-old APP/IFN-c Tg mice
with a single injection of Ab1-42 emulsified in CFA with or without
PTX. Mice were killed five weeks later, and their brains were
processed for immunohistochemistry and quantification of Ab,a s
described in Materials and Methods. T cells were visible only in
the brains of mice that had been immunized with Ab/CFA and
co-injected with PTX, and the T-cell pattern observed in those
brains (not shown here) was similar to that shown in Fig. 1. As
shown in Fig. 5A, Ab/CFA immunization without PTX acted
primarily to reduce diffuse forms of Ab plaques, whereas Ab/CFA
immunization with co-injected PTX was followed by almost
complete clearance of Ab from the brain. In three different regions
mediolateral to the bregma, stereological quantification of Ab
showed significantly reduced average amounts of Ab both without
(60% reduction) and with (97% reduction) PTX co-injection
(Fig. 5B, and Supplemental data, Fig. S1 and Table S1). No
significant clearance of Ab was observed in mice immunized with
PLP (Supplemental data, Fig. S5) or CFA alone (Supplemental
data, Fig. S6).
To gain an insight into the inflammatory milieu induced in
the brains of APP/IFN-c Tg mice after T cells had migrated to
sites of Ab plaques, we performed quantitative PCR analysis of
brain tissues from mice that had been immunized with Ab/CFA
and co-injected with PTX. Nonimmunized APP/IFN-c Tg mice
served as controls. Consistent with the Th1 phenotype of the
peripheral T-cell response and the accumulation of T cells
T-Cell Migration to Ab Plaques
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brain (by 39.7-fold), as was the case for the T-cell and
macrophage chemoattractant RANTES (by 39.8-fold) and the
IFN-c-inducible protein IP-10 (by 20.3-fold; Table 1). Expres-
sion of the MHC II invariant chain and of the costimulatory
molecule CD86 (Table 1) was also enhanced, suggesting that T
cells had not only migrated to the brain but had also undergone
activation at sites of Ab plaques, as indicated by their
morphology. Notably, although there was no increase in the
anti-inflammatory cytokines IL-10 and transforming growth
factor (TGF)- b, the proinflammatory cytokines IL-6 and TNF-a
were decreased (by about 3.3-fold) in the immunized mice
(Table 1). Moreover, the signal regulatory protein-b1( S I R P b1)
and the triggering receptor expressed on myeloid cells-2
(TREM2) – transmembrane molecules recently shown to be
associated with enhanced phagocytic activity of macrophages/
microglia [40,41] – were upregulated by 7.3-fold and 2.8-fold,
respectively (Table 1).
Discussion
The results of this study show that in a mouse model of AD, Ab-
specific lymphocytes occurred in the brain after a single Ab
immunization, provided that small amounts of IFN-c were
expressed in the brain. Although both T and B lymphocytes
crossed the vasculature into the perivascular space, only the T cells
were targeted to Ab plaques in the brain parenchymal tissue,
where they induced microglia activation and efficient clearance of
Ab. In contrast, PLP immunization resulted in T-cell accumula-
tion in the spinal cord and cerebellum, causing demyelination, but
not in the hippocampus, where Ab accumulated.
An important question that stems from the current study is why
Ab-reactive but not PLP-reactive T cells preferentially target Ab
plaques in the hippocampus. Several studies have previously
demonstrated the presence of perivascular cells capable of
presenting antigens to T cells in the endothelium of the brain
microvessels [7,42,43,44]. It is possible that these cells ensure that,
Figure 1. Ab immunization results in trafficking of T cells to sites of Ab plaques in the brain parenchyma. APP/IFN-c Tg mice aged 9
months were immunized with Ab and killed 19 days later. Brain sections were immunolabeled for Ab plaques co-localized with lymphocyte
subpopulations and activated microglia. (A) Brain sections derived from a representative Ab-immunized APP/IFN-c Tg mouse (n=11) were
immunolabeled with anti-CD4 (a, red), anti-Ab (b, blue), and anti-CD11b (c, green) antibodies. The merged panel is shown in d. Bar represents
200 mm. (B) Three-dimensional representation of Z-stalk images taken from a representative compact Ab plaque co-localized with CD11b
+ microglia
(green) and CD4 T cells (red) in the hippocampus. Bar represents 20 mm. (C) Co-localization analysis of CD4 T cells and CD11b-labeled plaques. Using
Volocity 3D image analysis software (Improvision, Waltham, MA, USA), we set an intensity threshold to mark only those areas with CD11b
high
microglia, representing Ab plaques. Columns represent percent CD11b-labeled plaques with and without co-localized CD4 T cells in each of the
analyzed sections [n=3 (3 brain sections per mouse); means 6 SD; P,0.001, Student’s t test].
doi:10.1371/journal.pone.0010830.g001
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brain-specific T cells enter the CNS. In such a case, the APCs – by
engulfing antigens in the brain vasculature – could facilitate both
the stimulation of specific CD8 and CD4 T cells (via MHC class I
and II, respectively) and the trafficking of these T cells to the
parenchyma. Ab is deposited in the vasculature throughout the
course of AD [45]. Furthermore, post-mortem examination of
brain sections of AD patients who had been immunized with Ab
showed a transient increase in the severity of cerebral amyloid
angiopathy, presumably as a consequence of enhanced drainage of
Ab into the vasculature [38]. Expression of TGF-b in the brain of
a mouse model of AD was also shown to result in the accumulation
of Ab in the cerebral blood vessels [46] and spontaneous
infiltration of T cells into the brain parenchyma, a process that
was significantly enhanced upon long-term Ab immunization [47].
It therefore seems likely that drainage of Ab into the perivascular
space and its local deposition there promote activation of Ab-
specific T cells, thereby enhancing the ability of these T cells, but
not of PLP-reactive T cells, to specifically target Ab plaques in the
parenchyma.
The T-cell responses observed in the current study in the brain
of a mouse model of AD differed in two important aspects from
those of EAE, in which myelin-specific T cells penetrate the CNS
and promote the demyelination of axons [5,6,8,48]. Firstly, the T-
cell response that we observed in the CNS did not lead to a
chronic influx of CD4 T cells into the CNS of our mouse model.
This finding might be explained by the fact that Ab deposits were
efficiently cleared from the brain and hence the lymphocyte
response was terminated. Secondly, our study clearly demonstrat-
ed that whereas PLP-specific T cells caused EAE lesions in the
spinal cord, Ab-specific T cells acted primarily to target amyloid
deposits in the brain: Ab-specific T cells in our study did not enter
the brain if there was no amyloid deposition there [16]. These data
suggest that unlike mouse models of MS where T cells penetrate
the intact CNS, Ab accumulation and deposition in the brain is a
precondition for triggering the entry of specific T cells upon
immunization.
The fact that Ab accumulates primarily in the hippocampus and
the frontal cortex also provides the Ab-specific T cells with a
parenchymal target for migration and activation. As shown in
Fig. 4, both CD4 T cells and, to a significantly smaller extent, CD8
T cells were targeted to sites of Ab plaques in the hippocampus.
CD4 T cells migrated towards sites of Ab accumulation and were
presumably restimulated there by microglia via MHC-II presen-
Figure 2. PLP immunization results in limited T-cell occurrence at the hippocampus of APP Tg mice. APP/IFN-c Tg mice aged 9 months
(n=5) were immunized with PLP and killed 19 days later. (A) Brain sections were analyzed for leukocyte infiltrates as described in Materials and
Methods. Sections were counterstained with TO-PRO 3 (blue). (a) Brain section showing infiltrating CD4 T cells (green) in the cerebellum. (b)
Magnified area of the cerebellum stained with Luxol Fast Blue, demonstrating areas with infiltrated cells and loss of myelin (black arrows). Bar
represents 200 mm. (B) Brain sections derived from a representative PLP-immunized APP/IFN-c Tg mouse were immunolabeled with anti-CD4 (a, red),
anti-CD11b (b, green), and anti-Ab (c, blue) antibodies. The merged panel is shown in d. Bar represents 200 mm. (C) Co-localization analysis of CD4 T
cells and Ab-labeled plaques. Using Volocity 3D image analysis software (Improvision, Waltham, MA, USA), we set an intensity threshold to mark only
those areas with Ab plaques. Columns represent percent Abplaques with and without co-localized CD4 T cells in each of the analyzed sections [n=3
(3 brain sections per mouse); means 6 SD].
doi:10.1371/journal.pone.0010830.g002
Figure 3. Ab or PLP vaccination of APP-Tg mice induces primarily a Th1 type of immune response. APP/IFN-c Tg mice aged 9–10 months
were injected subcutaneously with Ab (A) or PLP (B) emulsified in CFA in conjunction with PTX injections. Control mice were injected with CFA or left
untreated (A). Mice were killed 10 days later, and popliteal lymph nodes were harvested and analyzed for cytokine secretion by ELISA as described in
Materials and Methods. Lymph node derived cells were cultured without antigen or stimulated with increasing concentrations of Ab and PLP (0.1, 1
and 10 mg/ml). Secretion of IL-2, IFN-c, and IL-17A was measured after 24, 48, and 72 h in culture, respectively. Data obtained at 10 mg/ml Ab are
shown in A. The results shown in each case are the values obtained for three mice (means 6 SD) in one representative experiment of at least three
performed.
doi:10.1371/journal.pone.0010830.g003
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within the parenchymal tissue (Table 1). Because the mice in this
study were immunized with Ab1-42, it is possible that Ab-specific
CD8 T cells in the peripheral lymph nodes were also stimulated
and could thus migrate to the CNS via either endothelial or
dendritic cells presenting Ab on MHC-I. It is also possible that
CD8 T cells that migrate into the parenchyma interact with both
glia and neurons presenting Ab on MHC I. The specificity and
function of these cells in the brain of a mouse model of AD should
therefore be further investigated.
The role of T cells in the CNS tissue has been widely studied in
recent years. A growing body of evidence has indicated that T-
cell trafficking to the brains of APP-Tg mice overexpressing TGF-
b or IL-1b does not cause cellular or behavioral abnormalities
[47,49] and that brain-specific T cells can exhibit beneficial
effects by regulating the neuroinflammatory environment and the
mechanisms of neuronal protection and repair in several
neurodegenerative processes [10,11,12,13,15,16,18,50]. In the
present study, Ab-specific T cells displayed a Th1 phenotype in
that they secreted primarily IFN-c (Table 1), a key cytokine
required for stimulating the phagocytotic and degradative
activities of macrophages. Notably, both TREM2 and SIRPb1,
recently shown as DAP12-associated phagocytic receptors on
microglia [40,41], were upregulated by 2.8-fold and 7.3-fold,
respectively (Table 1). Furthermore, our quantitative PCR
analysis showed that this increased expression of TREM2 and
SIRPb1 was associated with decreased expression of TNFb and
IL-6, suggesting that the activation of microglia enhanced their
phagocytic function but the overall inflammatory process. Indeed,
Gaikwad et al. [41] have recently demonstrated that IFN-c
induces the expression of SIRPb1 in microglia and that activation
of SIRPb1 by specific antibodies enhances the uptake of fibrillar
Ab while suppressing lipopolysaccharide (LPS)-induced TNFa
secretion. Activation of Th1 cells in the brain, therefore,
presumably accounted for the activation of microglia and the
efficient clearance of Ab, as was previously achieved by
prophylactic periodic immunizations that evoked high titers of
Ab antibodies [51,52,53,54,55,56]. In light of the regulatory and
neuroprotective functions of IFN-c in the brain
[20,22,32,33,34,57,58], future studies should therefore address
the effects of such IFN-c-secreting T cells at sites of Ab plaques
on microglia function, the immune milieu induced locally, and
the consequent survival and function of adjacent neurons.
Even though it did not induce EAE, the lymphocytic reaction of
both B and T cells to Ab is potentially pathogenic because of the
risks of meningoencephalitis [59], entry of cytotoxic CD8 T cells
into the brain, strong proinflammatory cytokine profile of the
CD4-T cells [60], and brain hemorrhages caused by Ab antibodies
[61,62,63]. However, studies by our group have demonstrated a
remarkably increased frequency of Ab-specific T cells in healthy
older individuals and in patients with AD [25]. If the pathogenic
capacity of Ab-specific T cells can be neutralized, for example, by
using a bacteria-free or virus-free adjuvant such as alum or
incomplete Freund’s adjuvant, these T cells might play a clinical
role in promoting both Ab clearance and neuronal repair [19],
with minimal risk of adverse side effects.
Figure 4. Ab immunization results in immune-cell trafficking to the brain. APP/IFN-c. Tg mice aged 9 months were immunized with Ab and
killed 19 days later, and brain sections were immunolabeled as described in Materials and Methods. Lymphocyte subpopulations immunostained for
CD4 (A, green), CD8 (B, green), and CD19 (C, green, with red arrows indicating infiltrates in parenchymal vessels). Yellow arrowheads indicate
meningeal infiltrates. Sections were counterstained with TO-PRO 3 (blue). Bars represent 100 mm; inserts were taken with a 606objective lens. (D)
Overview of the hippocampal area (hippocampus and dentate gyrus indicated in yellow) showing CD4 (red) and CD8 (green) T cells co-localized with
Ab plaques (blue). Bar represents 100 mm. Higher magnification of Ab plaques (blue) co-localized with CD4 (red) and CD8 (green) T cells adjacent to a
parenchymal blood vessel in the dentate gyrus (E) and the CA1 (F) of the hippocampal formation. Bars represent 20 mm. Representative images from
eight mice are shown.
doi:10.1371/journal.pone.0010830.g004
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PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10830Figure 5. T-cell infiltrates in the parenchyma promote efficient clearance of existing Ab plaques. APP/IFN-c Tg mice aged 9 months were
immunized with Ab emulsified in CFA, Ab emulsified in CFA in conjunction with injection of PTX, or left untreated and examined 5 weeks later for Ab
in the brain. (A) Brain sections were immunolabeled with anti-Ab antibody (red) and counterstained with TO-PRO 3 (blue). A representative section
from each group is shown. (B) The amount of Ab in each group was quantified stereologically on 40-mm-thick sections using the Volocity 3S Image
Analysis software, as described in Materials and Methods and in Supplemental data, Fig. S4. One-tailed Student’s t-test revealed significant differences
between the three groups of mice (n=4 mice/group; *P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0010830.g005
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Figure S1 T-cell infiltrates in the parenchyma promote efficient
clearance of previously deposited Ab plaques. APP/IFN-c Tg
mice aged 9 months were immunized with Ab emulsified in CFA,
Ab emulsified in CFA in conjunction with PTX injections, or left
untreated, and examined 35 days later for Ab in the brain. Brain
sections were immunolabeled with anti-Ab antibody (red) and
counterstained with TO-PRO 3 (blue), as described in Materials
and Methods. A representative section from each group is shown
in A. Higher magnification (640) of the box in A is shown for each
group in panel B. Plaques are marked with colored lines if their
fluorescence intensity exceeds the threshold set by the classifier.
Found at: doi:10.1371/journal.pone.0010830.s001 (3.00 MB TIF)
Figure S2 Ab immunization results in trafficking of T cells to
sites of Ab plaques in the brain parenchyma. APP/IFN-c Tg mice
aged 9 months were immunized with Ab and killed 19 days later.
Brain sections were immunolabeled for Ab plaques co-localized
with lymphocyte subpopulations and activated microglia as
described for Fig. 1. The grayscale images with their correspond-
ing histograms are shown here at 106(a, c, and e; bars represent
200 mm) and 606(b, d, and f; bars represent 20 mm).
Found at: doi:10.1371/journal.pone.0010830.s002 (3.00 MB TIF)
Figure S3 PLP vaccination of APP/IFN-c Tg mice results in
immune-cell infiltration into the spinal cord and cerebellum. APP/
IFN-c Tg mice aged 9 months were vaccinated with PLP/CFA to
induce EAE, as described in Materials and Methods, and killed 19
days later. Spinal cord sections were immunolabeled with anti-
CD11b antibody (a and b, green), anti-CD11c antibody (c and d,
red), and anti-CD4 antibody (red in a and b and green in c and d)
and examined under the confocal microscope for inflammatory
foci. TO-PRO 3 was used for counterstaining (blue). (b and d)
Higher magnifications of inflammatory foci. Bars represent
100 mm in a and c and 20 mm in b and d.
Found at: doi:10.1371/journal.pone.0010830.s003 (3.00 MB TIF)
Figure S4 PLP immunization results in limited T-cell occur-
rence at the hippocampus of APP Tg mice. APP/IFN-c Tg mice
aged 9 months were immunized with PLP and killed 19 days later.
Brain sections were immunolabeled for Ab plaques co-localized
with lymphocyte subpopulations and activated microglia as
described for Fig. 1. The grayscale images with their correspond-
ing histograms are shown here at 106(a, c, and e; bars represent
200 mm) and 606(b, d, and f; bars represent 20 mm).
Found at: doi:10.1371/journal.pone.0010830.s004 (3.00 MB TIF)
Figure S5 PLP immunization of APP/IFN-c Tg mice promotes
a slight decrease in Ab load. APP/IFN-c mice aged 10 months
were left untreated or were immunized with PLP as described in
Methods, and killed after 19 days. Brains were removed, sectioned,
and immunolabeled with anti-Ab antibody (green) and counter-
stained with TO-PRO 3 (blue), as described in Materials and
Methods. Representative images of untreated (A) and PLP-
immunized (B) mice are shown. Eight sections from each brain
were immunolabeled for Ab and images were analyzed using the
Volocity 3D image analysis software. Columns represent the
fluorescent area in each brain section of the two analyzed groups
(n=3; means 6 SD; P.0.1, Student’s t-test). Bars represent
200 mm.
Found at: doi:10.1371/journal.pone.0010830.s005 (3.00 MB TIF)
Figure S6 A single subcutaneous injection of CFA fails to induce
significant clearance of Ab in APP/PS1/IFN-c Tg mice. APP/
PS1/IFN-c Tg mice aged 8–9 months were injected with CFA or
left untreated, as described in Materials and Methods. On day 19
after immunization mice were killed and brain sections were
immunolabeled with Ab antibodies. Eight sections representing
the entire brain were immunolabeled for Ab and images were
analyzed using the Volocity 3D image analysis software. Columns
represent the fluorescent area in each brain section of the two
analyzed groups (n=4; means 6 SD; P.0.5, Student’s t test).
Found at: doi:10.1371/journal.pone.0010830.s006 (3.00 MB TIF)
Table S1 Percent reduction of Ab according to the mediolateral
position in the hippocampus (%). APP/IFN-c Tg mice aged 9
months were immunized with Ab/CFA with and without co-
injection of pertussis toxin (PTX). Ab in brain sections was
quantified by immunohistochemical analysis as described in
Methods and Supplemental information, Fig. S3. Percent
reduction of Abwas calculated from the average of the
immunolabeled area at each mediolateral position of the
immunized mice.
Found at: doi:10.1371/journal.pone.0010830.s007 (0.03 MB
DOC)
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Table 1. Quantitative PCR analysis of immune factors in the
brains of Ab-immunized APP/IFN-c Tg mice.
Gene RQ P value
Antigen presentation
Invariant chain 12.7265.7 0.0148
CD86 5.563.3 0.0223
Immune regulators
INF-c 39.7618.9 0.0013
IL-6 0.360.12 0.0278
TNF-a 0.2960.05 0.0278
IL-10 undetected
TGF-b no difference
Chemokines
RANTES 39.8623.3 0.0075
IP-10 20.368.5 0.0020
Microglial activation
SIRP1b 7.360.15 0.0002
TREM2 2.860.03 0.0010
APP/IFN-c Tg mice aged 9 months were immunized with Ab/CFA and co-
injected twice with PTX as described in Methods. Untreated APP/IFN-c Tg mice
were used as controls. Mice were analyzed for gene expression in the brain by
quantitative PCR as described in Materials and Methods. For each of the genes
analyzed, the relative quantity (RQ) was calculated in relation to the level of
actin expression. Results are presented as average RQs of the expressed genes
in vaccinated mice relative to control mice. P values and SEM were calculated
from two immunized mice with substantial T-cell infiltrates in the brain
parenchyma and four untreated mice, using the 2-tailed Mann-Whitney test.
doi:10.1371/journal.pone.0010830.t001
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